Background Extracorporeal membrane oxygenation (ECMO) has been used extensively for coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS) …
For coronavirus disease 2019 (COVID-19), effective and well-understood treatment options are still scarce. Since vaccine efficacy is challenged by novel variants, short-lasting …
CE Burnett, TLH Okholm, I Tenvooren, DM Marquez… - Immunity, 2022 - cell.com
While studies have elucidated many pathophysiological elements of COVID-19, little is known about immunological changes during COVID-19 resolution. We analyzed immune …
J de Brabander, E Duijvelaar… - European …, 2022 - Eur Respiratory Soc
Background Imatinib reduced 90-day mortality in hospitalised coronavirus disease 2019 (COVID-19) patients in a recent clinical trial, but the biological effects that cause improved …
N Bruse, EJ Kooistra, A Jansen, RBE Van Amstel… - Critical Care, 2022 - Springer
Background A greater understanding of disease heterogeneity may facilitate precision medicine for coronavirus disease 2019 (COVID-19). Previous work identified four distinct …
Progress in improving cardiogenic shock (CS) outcomes may have been limited by failure to embrace the heterogeneity of pathophysiologic processes driving the underlying syndrome …
Immune Modulation in Sepsis, ARDS, and Covid-19 — The Road Traveled and the Road Ahead | NEJM Evidence Skip to main content NEJM Evidence homepage Advanced Search …
BA Kanwar, A Khattak, J Balentine, JH Lee, RE Kast - Vaccines, 2022 - mdpi.com
Since the start of the SARS-CoV-2 pandemic, refractory and relentless hypoxia as a consequence of exuberant lung inflammation and parenchymal damage remains the main …
MS Winkler, MF Osuchowski, D Payen, A Torres… - Critical Care, 2022 - Springer
The 40-year-old experience with glucocorticosteroids (GCs) in the context of severe infections is complex and troublesome. Recently, however, a clear indication for GCs in …